Seidl C - Search Results

1

Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis.

Essler M, Gärtner FC, Neff F, Blechert B, Senekowitsch-Schmidtke R, Bruchertseifer F, Morgenstern A, Seidl C. Essler M, et al. Among authors: seidl c. Eur J Nucl Med Mol Imaging. 2012 Apr;39(4):602-12. doi: 10.1007/s00259-011-2023-6. Epub 2012 Jan 12. Eur J Nucl Med Mol Imaging. 2012. PMID: 22237842

2

Highly specific tumor binding of a 213Bi-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional alpha-radioimmunotherapy of diffuse-type gastric cancer.

Senekowitsch-Schmidtke R, Schuhmacher C, Becker KF, Nikula TK, Seidl C, Becker I, Miederer M, Apostolidis C, Adam C, Huber R, Kremmer E, Fischer K, Schwaiger M. Senekowitsch-Schmidtke R, et al. Among authors: seidl c. Cancer Res. 2001 Apr 1;61(7):2804-8. Cancer Res. 2001. PMID: 11306447

3

Comparison of the radiotoxicity of two alpha-particle-emitting immunoconjugates, terbium-149 and bismuth-213, directed against a tumor-specific, exon 9 deleted (d9) E-cadherin adhesion protein.

Miederer M, Seidl C, Beyer GJ, Charlton DE, Vranjes-Duric S, Comor JJ, Huber R, Nikula T, Apostolidis C, Schuhmacher C, Becker KF, Senekowitsch-Schmidtke R. Miederer M, et al. Among authors: seidl c. Radiat Res. 2003 May;159(5):612-20. doi: 10.1667/0033-7587(2003)159[0612:cotrot]2.0.co;2. Radiat Res. 2003. PMID: 12710872

4

Locoregional alpha-radioimmunotherapy of intraperitoneal tumor cell dissemination using a tumor-specific monoclonal antibody.

Huber R, Seidl C, Schmid E, Seidenschwang S, Becker KF, Schuhmacher C, Apostolidis C, Nikula T, Kremmer E, Schwaiger M, Senekowitsch-Schmidtke R. Huber R, et al. Among authors: seidl c. Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3922S-8S. Clin Cancer Res. 2003. PMID: 14506190

5

Cell death triggered by alpha-emitting 213Bi-immunoconjugates in HSC45-M2 gastric cancer cells is different from apoptotic cell death.

Seidl C, Schröck H, Seidenschwang S, Beck R, Schmid E, Abend M, Becker KF, Apostolidis C, Nikula TK, Kremmer E, Schwaiger M, Senekowitsch-Schmidtke R. Seidl C, et al. Eur J Nucl Med Mol Imaging. 2005 Mar;32(3):274-85. doi: 10.1007/s00259-004-1653-3. Epub 2004 Oct 2. Eur J Nucl Med Mol Imaging. 2005. PMID: 15791436

6

Fractionated locoregional low-dose radioimmunotherapy improves survival in a mouse model of diffuse-type gastric cancer using a 213Bi-conjugated monoclonal antibody.

Bloechl S, Beck R, Seidl C, Morgenstern A, Schwaiger M, Senekowitsch-Schmidtke R. Bloechl S, et al. Among authors: seidl c. Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7070s-7074s. doi: 10.1158/1078-0432.CCR-1004-0017. Clin Cancer Res. 2005. PMID: 16203804

7

Differentiation of tumour and inflammation: characterisation of [methyl-3H]methionine (MET) and O-(2-[18F]fluoroethyl)-L-tyrosine (FET) uptake in human tumour and inflammatory cells.

Stöber B, Tanase U, Herz M, Seidl C, Schwaiger M, Senekowitsch-Schmidtke R. Stöber B, et al. Among authors: seidl c. Eur J Nucl Med Mol Imaging. 2006 Aug;33(8):932-9. doi: 10.1007/s00259-005-0047-5. Epub 2006 Apr 8. Eur J Nucl Med Mol Imaging. 2006. PMID: 16604346

8

Non-invasive visualisation of the development of peritoneal carcinomatosis and tumour regression after 213Bi-radioimmunotherapy using bioluminescence imaging.

Buchhorn HM, Seidl C, Beck R, Saur D, Apostolidis C, Morgenstern A, Schwaiger M, Senekowitsch-Schmidtke R. Buchhorn HM, et al. Among authors: seidl c. Eur J Nucl Med Mol Imaging. 2007 Jun;34(6):841-9. doi: 10.1007/s00259-006-0311-3. Epub 2007 Jan 6. Eur J Nucl Med Mol Imaging. 2007. PMID: 17206415

9

213Bi-radioimmunotherapy defeats early-stage disseminated gastric cancer in nude mice.

Beck R, Seidl C, Pfost B, Morgenstern A, Bruchertseifer F, Baum H, Schwaiger M, Senekowitsch-Schmidtke R. Beck R, et al. Among authors: seidl c. Cancer Sci. 2007 Aug;98(8):1215-22. doi: 10.1111/j.1349-7006.2007.00525.x. Epub 2007 Jun 11. Cancer Sci. 2007. PMID: 17561973 Free article.

10

213Bi-induced death of HSC45-M2 gastric cancer cells is characterized by G2 arrest and up-regulation of genes known to prevent apoptosis but induce necrosis and mitotic catastrophe.

Seidl C, Port M, Gilbertz KP, Morgenstern A, Bruchertseifer F, Schwaiger M, Röper B, Senekowitsch-Schmidtke R, Abend M. Seidl C, et al. Mol Cancer Ther. 2007 Aug;6(8):2346-59. doi: 10.1158/1535-7163.MCT-07-0132. Mol Cancer Ther. 2007. PMID: 17699730

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

223 results

Search Page